NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis $24.32 +0.51 (+2.14%) Closing price 04:00 PM EasternExtended Trading$24.34 +0.02 (+0.06%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About NewAmsterdam Pharma Stock (NASDAQ:NAMS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$23.96▼$25.1250-Day Range$21.16▼$31.7052-Week Range$21.02▼$42.21Volume2.27 million shsAverage Volume1.13 million shsMarket Capitalization$2.91 billionP/E RatioN/ADividend YieldN/APrice Target$49.73Consensus RatingModerate Buy Company Overview NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company’s lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters. Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments. NewAmsterdam has also studied obicetrapib in combination with ezetimibe and in other patient populations. The company’s development strategy is centered on providing additional oral treatment options for people who remain at elevated cardiovascular risk. NewAmsterdam Pharma was formed in 2019 and became a publicly traded company in 2022 through a business combination with Frazier Lifesciences Acquisition Corporation. The company operates internationally, with activities spanning the United States and Europe, and is led by Chief Executive Officer Michael Davidson, M.D., a physician and biotechnology executive with experience in cardiovascular drug development.AI Generated. May Contain Errors. Read More NewAmsterdam Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreNAMS MarketRank™: NewAmsterdam Pharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 194th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNewAmsterdam Pharma has a consensus price target of $49.73, representing about 102.6% upside from its current price of $24.55.Amount of Analyst CoverageNewAmsterdam Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NewAmsterdam Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($1.82) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NewAmsterdam Pharma is -11.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NewAmsterdam Pharma is -11.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NewAmsterdam Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.01% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 9.88.Change versus previous monthShort interest in NewAmsterdam Pharma has recently increased by 16.94%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.39 News SentimentNewAmsterdam Pharma has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for NewAmsterdam Pharma this week, compared to 4 articles on an average week.Search Interest3 people have searched for NAMS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have sold 2,809.48% more of their company's stock than they have bought. Specifically, they have bought $226,500.00 in company stock and sold $6,589,962.00 in company stock.Percentage Held by Insiders12.74% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NewAmsterdam Pharma's insider trading history. Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAMS Stock News HeadlinesNewAmsterdam Pharma: Can Obicetrapib's Data In Diabetes And Metabolic Syndrome Bring Back The Mojo?1 hour ago | rttnews.comNewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's DiseaseSeptember 29 at 6:13 PM | finance.yahoo.comShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-free qualified withdrawals, and no lifetime required minimum distributions. The catch: converting triggers ordinary income tax in the year you convert, and the decision cannot be reversed. The right move depends on your income, tax bracket, and retirement timeline.September 30 at 1:00 AM | SmartAsset (Ad)NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s DiseaseSeptember 29 at 6:13 PM | markets.businessinsider.comNewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's DiseaseSeptember 29 at 8:00 AM | globenewswire.comNewAmsterdam Pharma Company NV (NAMS)September 27 at 8:57 AM | za.investing.comInsider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Buys $226,500.00 in StockSeptember 16, 2026 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Sells $40,512.00 in StockSeptember 10, 2026 | insidertrades.comSee More Headlines NAMS Stock Analysis - Frequently Asked Questions How have NAMS shares performed this year? NewAmsterdam Pharma's stock was trading at $35.08 at the beginning of the year. Since then, NAMS stock has decreased by 30.0% and is now trading at $24.5460. How were NewAmsterdam Pharma's earnings last quarter? NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.04. The business had revenue of $3.70 million for the quarter, compared to analysts' expectations of $2.83 million. NewAmsterdam Pharma had a negative trailing twelve-month return on equity of 34.81% and a negative net margin of 3,644.21%. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NewAmsterdam Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), Pimco Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX). Company Calendar Last Earnings8/05/2026Today9/30/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, NAMS's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NAMS CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees100Year Founded2019Price Target and Rating Average Price Target for NewAmsterdam Pharma$49.73 High Price Target$58.00 Low Price Target$37.00 Potential Upside/Downside+103.7%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$203.82 million Net Margins-3,644.21% Pretax Margin-3,644.21% Return on Equity-34.81% Return on Assets-31.50% Debt Debt-to-Equity RatioN/A Current Ratio9.03 Quick Ratio9.03 Sales & Book Value Annual Sales$7.12 million Price / Sales409.74 Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book4.09Miscellaneous Outstanding Shares119,537,000Free Float104,308,000Market Cap$2.92 billion OptionableOptionable Beta0.09 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:NAMS) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMS Stock Alerts